{"title":"多组学分析了长双歧杆菌亚种的作用。对超重和肥胖受试者补充longum BL21：一项随机、双盲、安慰剂对照研究。","authors":"Xiaoya Wang, Zefeng Xing, Rui Wang, Guoming Zhang, Guodong Liu, Zhen Li, Lixiang Li","doi":"10.1186/s12986-025-00969-2","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Bifidobacterium longum subsp. longum BL21 has demonstrated promise in alleviating gut microbiota disturbances and metabolic regulation in high-fat diet-induced obesity and type 2 diabetes mellitus models. However, the effect of probiotic B. longum BL21 on overweight and obese individuals remain unclear.</p><p><strong>Methods: </strong>A randomized, double-blind, placebo-controlled trial was performed, and 66 adult individuals were assigned to receive either BL 21 (2*10<sup>10</sup> colony-forming units per day along with 3 g of maltodextrin) or placebo (3 g of maltodextrin daily) for 8 weeks. Multi-omics analyses were employed to evaluate the impact of the B. longum strain BL21 on gut microbiota, serum metabolomics, body weight and lipids profiles in overweight and obese participants.</p><p><strong>Results: </strong>Following the intervention, both the BL21 group (1.22 ± 2.78, P = 0.02) and placebo group (0.98 ± 2.06, P = 0.01) demonstrated significant body weight reductions, with no statistically significant intergroup difference observed (P = 0.81). Notably, only the BL21 group exhibited a significant reduction in triglyceride levels compared to baseline (0.21 ± 1.09, P = 0.04). Microbiota analysis indicated that BL21 intervention significantly changed the β-diversity at week 8 compared with placebo group. The genera of Parasutterella, Parabacteroides, Blautia, Dorea, Butyricicoccus enriched in BL21 group. Metabolomics results indicated that sphingolipid metabolism, biotin metabolism and protein digestion and absorption were the top altered pathway in BL21 group compared with placebo group after intervention.</p><p><strong>Conclusion: </strong>B. longum subsp. longum BL21 may be a beneficial candidate to modulate the gut microbiota and triglyceride metabolism of overweight and obese individuals.</p><p><strong>Trial registration: </strong>Clinical trial registration number: NCT06140641. Date of registration: November 17, 2023.</p>","PeriodicalId":19196,"journal":{"name":"Nutrition & Metabolism","volume":"22 1","pages":"79"},"PeriodicalIF":4.1000,"publicationDate":"2025-07-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12273011/pdf/","citationCount":"0","resultStr":"{\"title\":\"Multi-omics analyses the effect of Bifidobacterium longum subsp. longum BL21 supplementation on overweight and obese subjects: a randomized, double-blind, placebo-controlled study.\",\"authors\":\"Xiaoya Wang, Zefeng Xing, Rui Wang, Guoming Zhang, Guodong Liu, Zhen Li, Lixiang Li\",\"doi\":\"10.1186/s12986-025-00969-2\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Bifidobacterium longum subsp. longum BL21 has demonstrated promise in alleviating gut microbiota disturbances and metabolic regulation in high-fat diet-induced obesity and type 2 diabetes mellitus models. However, the effect of probiotic B. longum BL21 on overweight and obese individuals remain unclear.</p><p><strong>Methods: </strong>A randomized, double-blind, placebo-controlled trial was performed, and 66 adult individuals were assigned to receive either BL 21 (2*10<sup>10</sup> colony-forming units per day along with 3 g of maltodextrin) or placebo (3 g of maltodextrin daily) for 8 weeks. Multi-omics analyses were employed to evaluate the impact of the B. longum strain BL21 on gut microbiota, serum metabolomics, body weight and lipids profiles in overweight and obese participants.</p><p><strong>Results: </strong>Following the intervention, both the BL21 group (1.22 ± 2.78, P = 0.02) and placebo group (0.98 ± 2.06, P = 0.01) demonstrated significant body weight reductions, with no statistically significant intergroup difference observed (P = 0.81). Notably, only the BL21 group exhibited a significant reduction in triglyceride levels compared to baseline (0.21 ± 1.09, P = 0.04). Microbiota analysis indicated that BL21 intervention significantly changed the β-diversity at week 8 compared with placebo group. The genera of Parasutterella, Parabacteroides, Blautia, Dorea, Butyricicoccus enriched in BL21 group. Metabolomics results indicated that sphingolipid metabolism, biotin metabolism and protein digestion and absorption were the top altered pathway in BL21 group compared with placebo group after intervention.</p><p><strong>Conclusion: </strong>B. longum subsp. longum BL21 may be a beneficial candidate to modulate the gut microbiota and triglyceride metabolism of overweight and obese individuals.</p><p><strong>Trial registration: </strong>Clinical trial registration number: NCT06140641. Date of registration: November 17, 2023.</p>\",\"PeriodicalId\":19196,\"journal\":{\"name\":\"Nutrition & Metabolism\",\"volume\":\"22 1\",\"pages\":\"79\"},\"PeriodicalIF\":4.1000,\"publicationDate\":\"2025-07-17\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12273011/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Nutrition & Metabolism\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1186/s12986-025-00969-2\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"NUTRITION & DIETETICS\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Nutrition & Metabolism","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1186/s12986-025-00969-2","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"NUTRITION & DIETETICS","Score":null,"Total":0}
Multi-omics analyses the effect of Bifidobacterium longum subsp. longum BL21 supplementation on overweight and obese subjects: a randomized, double-blind, placebo-controlled study.
Background: Bifidobacterium longum subsp. longum BL21 has demonstrated promise in alleviating gut microbiota disturbances and metabolic regulation in high-fat diet-induced obesity and type 2 diabetes mellitus models. However, the effect of probiotic B. longum BL21 on overweight and obese individuals remain unclear.
Methods: A randomized, double-blind, placebo-controlled trial was performed, and 66 adult individuals were assigned to receive either BL 21 (2*1010 colony-forming units per day along with 3 g of maltodextrin) or placebo (3 g of maltodextrin daily) for 8 weeks. Multi-omics analyses were employed to evaluate the impact of the B. longum strain BL21 on gut microbiota, serum metabolomics, body weight and lipids profiles in overweight and obese participants.
Results: Following the intervention, both the BL21 group (1.22 ± 2.78, P = 0.02) and placebo group (0.98 ± 2.06, P = 0.01) demonstrated significant body weight reductions, with no statistically significant intergroup difference observed (P = 0.81). Notably, only the BL21 group exhibited a significant reduction in triglyceride levels compared to baseline (0.21 ± 1.09, P = 0.04). Microbiota analysis indicated that BL21 intervention significantly changed the β-diversity at week 8 compared with placebo group. The genera of Parasutterella, Parabacteroides, Blautia, Dorea, Butyricicoccus enriched in BL21 group. Metabolomics results indicated that sphingolipid metabolism, biotin metabolism and protein digestion and absorption were the top altered pathway in BL21 group compared with placebo group after intervention.
Conclusion: B. longum subsp. longum BL21 may be a beneficial candidate to modulate the gut microbiota and triglyceride metabolism of overweight and obese individuals.
Trial registration: Clinical trial registration number: NCT06140641. Date of registration: November 17, 2023.
期刊介绍：
Nutrition & Metabolism publishes studies with a clear focus on nutrition and metabolism with applications ranging from nutrition needs, exercise physiology, clinical and population studies, as well as the underlying mechanisms in these aspects.
The areas of interest for Nutrition & Metabolism encompass studies in molecular nutrition in the context of obesity, diabetes, lipedemias, metabolic syndrome and exercise physiology. Manuscripts related to molecular, cellular and human metabolism, nutrient sensing and nutrient–gene interactions are also in interest, as are submissions that have employed new and innovative strategies like metabolomics/lipidomics or other omic-based biomarkers to predict nutritional status and metabolic diseases.
Key areas we wish to encourage submissions from include:
-how diet and specific nutrients interact with genes, proteins or metabolites to influence metabolic phenotypes and disease outcomes;
-the role of epigenetic factors and the microbiome in the pathogenesis of metabolic diseases and their influence on metabolic responses to diet and food components;
-how diet and other environmental factors affect epigenetics and microbiota; the extent to which genetic and nongenetic factors modify personal metabolic responses to diet and food compositions and the mechanisms involved;
-how specific biologic networks and nutrient sensing mechanisms attribute to metabolic variability.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
